The PD-L1 and TLR7 dual-targeting nanobody-drug conjugate exerts potent antitumor efficacy by orchestrating innate and adaptive immune responses
X. Yu, Y. Long, B. Chen…·L. Gong
The paper develops a PD-L1 and TLR7 dual-targeting nanobody-drug conjugate that synergistically activates innate and adaptive immune responses, showing potent antitumor effects in both 'hot' and 'cold' tumors.